Immunic (IMUX) vs PMV Pharmaceuticals (PMVP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PMV Pharmaceuticals (PMVP) has outperformed Immunic (IMUX) over the past year, gaining 4.9% versus a loss of 15.8%. Over five years, IMUX leads with a -91.3% price change compared with -93.8% for PMVP. PMV Pharmaceuticals is the larger company by market cap ($112.5 million vs $103.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMUX | PMVP |
|---|---|---|
| Share price | $7.56 | $1.49 |
| Market cap | $103.15M | $112.51M |
| 1-day change | -0.92% | -0.67% |
| YTD return | +41.57% | +19.20% |
| 1-year return | -15.81% | +4.93% |
| 5-year return | -91.28% | -93.78% |
| EPS (TTM) | $-3.83 | $-1.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.43 | $1.91 |
| 52-week low | $5.06 | $1.02 |
| Distance from 52-week high | -56.63% | -21.99% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +469.97% | +181.88% |
| Average volume | 284.68K | 661.39K |
| Shares outstanding | 13.64M | 75.51M |
| Employees | 100 | 54 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PMVP has outperformed IMUX by 20.7 percentage points over the past year.
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Healthcare · Biotechnology · 100 employees
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Healthcare · Biotechnology · 54 employees
IMUX vs PMVP FAQ
Which is bigger, Immunic or PMV Pharmaceuticals?
PMV Pharmaceuticals (PMVP) is larger, with a market capitalization of $112.51M compared with $103.15M for Immunic (IMUX).
Which stock has performed better over the past year, IMUX or PMVP?
PMVP returned +4.93% over the past 12 months, compared with -15.81% for IMUX (price return, excluding dividends). Past performance does not predict future results.
Are Immunic and PMV Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.